| 000 | 01588 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250514231829.0 | ||
| 264 | 0 | _c20050929 | |
| 008 | 200509s 0 0 eng d | ||
| 022 | _a0300-0664 | ||
| 024 | 7 |
_a10.1111/j.1365-2265.2005.02293.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBiswas, M | |
| 245 | 0 | 0 |
_aLong-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. _h[electronic resource] |
| 260 |
_bClinical endocrinology _cJul 2005 |
||
| 300 |
_a26-31 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBromocriptine _xtherapeutic use |
| 650 | 0 | 4 | _aCabergoline |
| 650 | 0 | 4 |
_aDopamine Agonists _xtherapeutic use |
| 650 | 0 | 4 |
_aErgolines _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPituitary Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aProlactinoma _xdrug therapy |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aSmith, J | |
| 700 | 1 | _aJadon, D | |
| 700 | 1 | _aMcEwan, P | |
| 700 | 1 | _aRees, D A | |
| 700 | 1 | _aEvans, L M | |
| 700 | 1 | _aScanlon, M F | |
| 700 | 1 | _aDavies, J S | |
| 773 | 0 |
_tClinical endocrinology _gvol. 63 _gno. 1 _gp. 26-31 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2265.2005.02293.x _zAvailable from publisher's website |
| 999 |
_c15621567 _d15621567 |
||